INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inflammatory disease. Insufficiently treated, it causes permanent tissue damage, joint deformities, functional impairments, reduced quality of life and premature death, mainly due to cardiovascular disease [1] [2] [3] [4] . Although a positive test for rheumatoid factor (RF), i.e. autoantibodies against the Fc portion of immunoglobulin G (IgG-Fc), is a diagnostic and prognostic seromarker of RA [5] [6] [7] , the serum levels of RF do not reflect disease activity. Most studies comparing RF with IgGclass antibodies to citrullinated proteins/peptides (ACPA), show that the latter are not only superior as diagnostic markers of RA, but also better predictors of disease course and outcome, and identify a uniform group of RA patients [8] [9] [10] [11] [12] . Both of these tests, without specifying antibody isotype or target antigen, serve as markers of RA according to the 2010 Euro-American Classification criteria [13] , but "seropositive RA" still refers to RF-positive cases according to the World Health Organization International Classification of Diagnoses (ICD-10).
To most part, the clinical experience of RF refers to antibodies agglutinating IgGsensitized particles. Although agglutination tests do not specify the RF-isotype, a positive test mainly implies IgM-class antibodies. Isotype-specific RF tests are also available, and it has been claimed that IgA-RF (especially in combination with IgM-RF) is a better prognostic seromarker than IgM-RF alone [14] . To qualify as an autoantibody, human RF with affinity for human IgG-FchIgG-Fcshould be demonstrated. Although this was done already in the pioneering experiments by Kunkel et al., and although IgG-RFs were suggested by this group already in the early 1960s [15] , IgG-RF tests detecting antibodies against hIgG-Fc are not readily accessible in clinical routine diagnostics, mainly due to methodological limitations. Specifically, assays for IgG-RF using human IgG as the antigen cannot utilize anti-human IgG-Fc detection antibodies, since they per se act as RFs. Nevertheless, it has been argued that IgG-RF is of special pathogenic interest [16, 17] .
The present study was undertaken to develop novel IgG-RF analyses without specifying the RF subclass, but to analyze RF-specificity against recombinant human IgG-Fc of the four different subclasses in early RA.
MATERIALS AND METHODS

Subjects
The serum bank of the prospective Swedish early arthritis study "TIRA-1" [9] was utilized, i.e. sera from clinically well characterized patients with a diagnosis of early (onset of first joint swelling ≤ 12 months) RA. The sera were drawn at the time for inclusion in the TIRA-1 cohort during 1997-1998, and stored at -70°C. Before the planning of the present study, inclusion sera had been analyzed for the presence of RF measured by latex-particle agglutination, by ELISA regarding IgA-and IgM-class RF, and for IgG-class antibodies against the second generation cyclic citrullinated peptides (anti-CCP2, EuroDiagnostica, Arnhem, Holland) [9] . For the present study, inclusion sera from 20 patients seropositive regarding IgM-and IgA-RF together with a positive test for IgG anti-CCP (henceforth designated 'double-positive') were selected, as well as 20 sera from patients testing negative with the same autoantibody analyses ('double-negative').
Characteristics of the 40 TIRA-1 patients are summarized in Table 1 . Sera from 20 healthy blood donors were used as reference. All studies involving the TIRA-based 5 material and control subjects have been approved by the regional ethics committee in Linköping, Sweden (Dnr 96-035; 01-169; M32-05; M144-05; M168-05). The TIRA biobank is approved by the Swedish National Board of Health and Welfare (SoS-1).
IgG-RF enzyme-linked immunosorbent assay (ELISA)
All serum samples were analyzed in triplicate, and the individual results expressed as mean values. The RF target antigens, hIgG-Fc subclasses 1-4, respectively, were expressed in a eukaryotic host (Pichia pastoris) and purified as previously described [18] . 
RESULTS
IgG-RF subclass specificity
DISCUSSION
Rheumatoid factor is a family of autoantibodies with great diversity regarding idiotypic specificity as well as antibody isotype and subclass. RFs can be induced by T-cell dependent as well as T-cell independent B-cell activation and hypermutation, probably even outside germinal centres [19] . Immunization with a variety of antigens (e.g. during infection or upon vaccination) can initiate RF production. This is likely to result from IgG antibody development and immune complex formation, and it has been implied that the stimulating Fc-gamma receptor (FcR) IIa and the inhibitory FcRIIb are crucial for RF formation and regulation [20, 21] . In this study we analyzed subclass-specific IgG-RF in sera from patients with early (<12 months from arthritis onset) RA, comparing seropositive cases (as defined by a positive IgM-and IgA-RF at inclusion) with seronegative. All of the selected IgM/IgA-RF positive cases were also positive regarding IgG anti-CCP, whereas the IgM/IgA-RF negative cases were consistently anti-CCP negative. Using human recombinant glycosylated antigens (Fc1-4) and chicken anti-human IgG-Fab, we found evidence of raised levels of IgG-RF against IgG of subclasses 1 and 2, but no evidence of IgG-RF against IgG3 or IgG4.
The first isotype-specific RF tests using ELISAs or radio-immunoassays (RIAs) were introduced already in the 1970s [22] [23] [24] . However, analysis of IgG-RF using human IgG (hIgG) as the source of antigen requires careful assay design, since both hIgG and IgG-RF may be recognized by the detection antibody. Instead, rabbit IgG is often used as source of antigen, for instance bound to microtitre plates coated with bovine serum albumin (BSA), followed by attachment of rabbit IgG anti-BSA antibodies [25] . BSA is often utilized also in other immunoassays to prevent non-specific surface attachment of immunoglobulins. In order to prevent false positive reactions due to occurrence of anti-BSA antibodies in serum, the dilution buffers also contain BSA which neutralizes the anti-BSA antibodies. Notably, however, this formation of BSA-anti-BSA complexes may in turn also neutralize RF. Since anti-BSA antibodies are commonplace [26] and considering the risks of erroneous results due to their presence [27, 28] Similar RF affinity patterns as those presented here have previously been described for IgM-and IgG-class RFs derived from RA patients [30, 31] . Elson et al., who studied the subclass specificity of human IgG-RF using intact hIgG3 and hIgG4 and heterogeneous pools of hIg1-Fc and hIgG2-Fc as antigens and BSA as a blocking agent, found positive IgG-RF with the target-antigen pattern IgG1≈IgG2>IgG3=IgG4. In their study, levels of IgG1-and IgG2-specific RF were significantly raised in relation to healthy donors, and solely in the patients with extraarticular disease (nodules, vasculitis or Felty's syndrome) [30] . Miyata et al., who used intact hIgG1-4 as antigen and tested sera from 8 patients with established RA and 7 previously tested IgG-RF positive sera from healthy subjects, reported that IgG-RF was predominantly found in the IgG1 fraction [32] . Contrasting to most other studies on IgG-RF reactivity, Tokano et al., reported that a substantial proportion (8 of 49) of RA patients had IgG-RF recognizing IgG3 [33] . The reasons for the discrepancies between the different studies are not obvious, but may be sought in differences in the patient populations, medication strategies and immunoassay designs.
In contrast to previous studies on subclass-specificity of IgG-RF, we investigated sera from patients with recent onset arthritis at the time for RA diagnosis (before treatment with disease-modifying agents), and consistently used molecularly homogenous, recombinant hIgG-Fc fragments as antigen substrates and Tween-20 to prevent nonspecific immunoglobulin binding. In our setup with subclass-specific hIgG-Fc fragments, we conclude that IgG-RF specific for IgG2 is pronounced in seropositive RA (as defined by IgM-and IgA-RF ELISAs) and that it coincides strongly with IgM-class RF. We also found evidence of IgG1-specific IgG-RF occurrence without significant correlation to IgM-or IgA-RF, but no signs of IgG3-or IgG4-specific IgG-RF using sera from healthy blood donors as reference material. It cannot be excluded however, that IgM-RF and/or IgA-RF interfere with IgG-RF binding (and vice versa). As regards the level of IgG1-specific RFs, it may have been overestimated due to the tendency of IgG1 form Fc-Fc interactions in the solid-phase assay [34] , a phenomenon that has recently been reported to be inhibited by the addition of Fc-derived peptides from IgG1, IgG2, and IgG4 [35] .
Furthermore, IgG4, which constitutes only a small fraction of total circulating IgG, has often been recognized as an "RF", but this is probably to great extent explained by the tendency of IgG4 to form aggregates due to Fc-Fc interactions [36] . In the present study, however, IgG4-RFs were rare. Yet, it is possible that such Fc interactions could contribute to the relatively high OD values for healthy donors and double-negative 11 patients. Furthermore, it cannot be excluded that the high background levels observed in the reference sera regarding reactivity with IgG1, IgG3 and IgG4, may actually reflect occurrence of IgG-RFs in healthy individuals. Apart from additional studies on IgM-and IgA-depleted sera, inclusion of trace amounts of pepsin [36] may give further information on the antigen-specificity of IgG-RFs.
To conclude, we present a novel approach for subclass-specific IgG-RF analysis using a panel of recombinant hIgG(1-4)-Fc fragments. Our study showed IgG1-and IgG2-specific IgG-RF in seropositive rheumatoid arthritis. Future studies on larger patient groups, and analysis of consecutive serum samples together with data on disease course and outcome measures will be needed to evaluate the diagnostic and prognostic potentials of subclass-specific IgG-RF analysis. Figure 1 
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